Anti-Inflammatory Diet Home Page...
 
Web Level1Diet.com
Subscribe to Anti-Inflammatory Diet RSS feeds...
Subscribe
Free Anti-inflammatory diet summary... Anti-inflammation diet weight loss story... 
Home Foods to Eat Foods to Avoid Exercise Supplements Weight Loss News Diabetes News Your Concerns Archived Reports

Bookmark Us: Yahoo Del.icio.us Simpy Technorati Email a friend Print

Regimen
Health Information Search Results

Matching Summaries of Recent
Peer Reviewed Scientific Research Reports.


Refine Your Search:

All Words Any Words
Search Again By Year -- Simply add a space, then the year you want to your search term.
 


 << Prev 20  Showing 1 to 20 of 67 Matches Next 20 >>



1. Durability of adherence to antiretroviral therapy on initial and subsequent regimens.
Match Strength: 6.255

There is uncertainty regarding the durability of adherence to antiretroviral therapy. This study is a retrospective review of previously antiretroviral naive patients initiating therapy between 1997 and 2002. Antiretroviral adherence was calculated using prescription refill data and was analyzed over time on an initial regimen and on sequential antiretroviral regimens. Three hundred forty-four patients were included. The median lengths of the first, second, and third regimens were stable at 1.7 years, 1.2 years, and 1.5 years, respectively (p = 0.10). In multivariate analysis the factor most ... Read More »
» Published in AIDS Patient Care STDS. 2006 Sep;20(9):628-36.

2. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group.
Match Strength: 5.510

This study describes the magnitude of risk of therapy-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) in 578 individuals diagnosed with Ewing sarcoma and enrolled on Children's Oncology Group therapeutic protocol, INT-0091. Between 1988 and 1992, patients with or without metastatic disease were randomized to receive doxorubicin, vincristine, cyclophosphamide, and dactinomycin (regimen A) or these 4 drugs alternating with etoposide and ifosfamide (regimen B). Between 1992 and 1994, patients with metastatic disease were nonrandomly assigned to receive high-intensity therapy ... Read More »
» Published in Blood. 2007 Jan 1;109(1):46-51. Epub 2006 Sep 19.

3. Comprehensive findings on clinical, bacteriological, histopathological and therapeutic aspects of cutaneous tuberculosis.
Match Strength: 4.912

OBJECTIVE: To define the bacteriological and histological correlates of the three predominant clinical forms of cutaneous tuberculosis and to evaluate the efficacy of a 9-month daily regimen containing rifampicin and isoniazid. METHODS: In the dermatological clinics of two major teaching hospitals in Chennai, 213 patients with suspected clinical manifestations of cutaneous tuberculosis underwent examination and a skin biopsy for bacteriological and histological tests. They were treated with a daily regimen of rifampicin and isoniazid for 9 months and follow-up for 3 years. RESULTS: ... Read More »
» Published in Trop Med Int Health. 2006 Oct;11(10):1521-8.

4. Logistics of therapy with the ibritumomab tiuxetan regimen.
Match Strength: 4.828

Radioimmunotherapy is an important new modality for treating patients with B-cell non-Hodgkin's lymphoma (NHL). Clinical trials have shown the safety and efficacy of agents that deliver radiation directly to malignant cells by attaching the (131)I or (90)Y radionuclide to monoclonal antibodies against CD20. In clinical trials, (90)Y ibritumomab tiuxetan has produced rates of response as high as 83% in patients with relapsed or refractory CD20+ NHL. The ibritumomab tiuxetan regimen is conveniently given in an outpatient setting over the course of 7-9 days. This article describes the logistics ... Read More »
» Published in Int J Radiat Oncol Biol Phys. 2006;66(2 Suppl):S35-8.

5. Medication persistence with weekly versus daily doses of orally administered bisphosphonates.
Match Strength: 4.341

OBJECTIVE: To compare medication persistence among patients receiving daily orally administered bisphosphonates with persistence among patients receiving weekly orally administered bisphosphonates to ascertain whether less frequent dosing is associated with better long-term treatment persistence. METHODS: A large, longitudinal cohort of female patients (N = 211,319) receiving prescriptions for alendronate or risedronate from approximately 14,000 US retail pharmacies was assessed. Medication persistence was defined as the percentage of patients who continued to take bisphosphonate therapy ... Read More »
» Published in Endocr Pract. 2006 Sep-Oct;12(5):522-8.

6. A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.
Match Strength: 4.195

This study was aimed to investigate the factors influencing long-term survival on patients with acute promyelocytic leukemia. Here, we present a single center retrospective study with long-term follow-up to explore the prognostic factors and a rationale of the using of ATRA, chemotherapy and As(2)O(3) in the treatment of newly diagnosed APL patients. In total, 222 patients, 184 achieved complete remission (CR) with the CR rate of 82.88% and 22 patients died during early induction therapy with the early-death-rate of 10%. Total 171 newly diagnosed APL patients entering CR were retrospectively ... Read More »
» Published in Leuk Res. 2006 Sep 26;

7. Therapeutic drug monitoring of cyclosporine Neoral in de novo Chinese cardiac transplant recipients treated with an everolimus-cyclosporine immunosuppressive regimen.
Match Strength: 4.029

This study determined cyclosporine Neoral (CsA) pharmacokinetics and the accuracy of a limited sampling strategy to predict the 12-hour CsA area-under-the-curve (AUC) to provide a practical method for more accurate therapeutic drug monitor of CsA among de novo Chinese heart transplant recipients treated with an everolimus-CsA immunosuppressive regimen. METHODS: Blood samples were collected at 0, 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours after oral administration of CsA in six de novo heart recipients receiving a CsA, everolimus, and methylprenisolone immunosuppressive regimen after rabbit ... Read More »
» Published in Transplant Proc. 2006 Sep;38(7):2132-4.

8. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients.
Match Strength: 3.960

The objectives of this study were to develop a meropenem population pharmacokinetic model using patient data and use it to explore alternative dosage regimens that could optimize the currently used dosing regimen to achieve higher likelihood of pharmacodynamic exposure against pathogenic bacteria. We gathered concentration data from 79 patients (ages 18-93 years) who received meropenem 0.5, 1, or 2 g over 0.5- or 3-hour infusion every 8 hours. Meropenem population pharmacokinetic analysis was performed using the NONMEM program. A 2-compartment model fit the data best. Creatinine clearance, age ... Read More »
» Published in J Clin Pharmacol. 2006 Oct;46(10):1171-8.

9. Differences between the different conditioning regimens for allogeneic stem cell transplantation.
Match Strength: 3.847

PURPOSE OF REVIEW: The aim of this article is to compare the differences in efficacy and toxicity between the various conditioning regimens for allogeneic stem cell transplantation. RECENT FINDINGS: Several studies, all retrospective, that compare the impact of various different conditioning regimens amongst each other are presented. Reduced intensity conditioning apparently lowered transplant-related mortality in patients with minimal residual disease who were at high risk for treatment-related mortality. In contrast, patients with active disease could only be salvaged when a myeloablative ... Read More »
» Published in Curr Opin Oncol. 2006 Nov;18(6):667-70.

10. Graft reepithelialization after penetrating keratoplasty using organ-cultured donor tissue.
Match Strength: 3.782

OBJECTIVE: To analyze graft reepithelialization after penetrating keratoplasty using organ-cultured donor tissue. DESIGN: Retrospective observational cohort study. PARTICIPANTS: One thousand one hundred thirty-eight consecutive penetrating keratoplasties (1003 patients) performed between 1992 and 2004 were analyzed, and 1003 were included (1 graft per patient was included). METHODS: Slit-lamp examination after fluorescein staining. MAIN OUTCOME MEASURE: Graft reepithelialization time was recorded. RESULTS: The average graft reepithelialization time was 4.6+/-13.2 days (range, 1-210 days; ... Read More »
» Published in Ophthalmology. 2006 Dec;113(12):2181-6. Epub 2006 Sep 25.

11. Experience of the treatment with gemcitabine, docetaxel, and carboplatin (GDC) chemotherapy for patients with small-cell carcinoma of the prostate.
Match Strength: 3.569

Small-cell carcinoma of the prostate (SCCP) is a rare entity. Many treatment modalities have been done, but thus far no uniform treatment has been clearly established. We carried out combination chemotherapy with gemcitabine, docetaxel, and carboplatin (GDC) regimen (for two patients with refractory SCCP. Case 1 involved a 53-year-old man diagnosed with SCCP after receiving hormone therapy for prostate cancer (stage D1). Six cycles of GDC chemotherapy was applied. Initially the primary site reduced according with a decline of neuro-specific enolase and with relief of the symptoms; however, ... Read More »
» Published in Int J Urol. 2006 Sep;13(9):1254-8.

12. Successful HIV Treatment: Lessons Learned.
Match Strength: 3.463

OBJECTIVE: To review current insights concerning treatment of human immunodeficiency virus (HIV). SUMMARY: The range of antiretroviral agents available for treating patients who have HIV/AIDS (acquired immunodeficiency syndrome) has expanded to 20 medications since the first, zidovudine, was approved in 1987. While the exact choice of drugs to use in treatment must be tailored to the patient, depending on safety and tolerance, the ultimate goal is durable suppression of the HIV virus. Highly active antiretroviral treatment (HAART) is the current standard of care and involves treating the ... Read More »
» Published in J Manag Care Pharm. 2006 Sep;12(7 Suppl B):6-11.

13. Assessing regimen adherence of adolescents with type 1 diabetes.
Match Strength: 3.321

OBJECTIVE: The purpose of this study is to evaluate two updated measures of diabetes regimen adherence. The Diabetes Self-Management Profile (DSMP) is a widely used, structured interview. Limitations include a substantial interviewer and respondent time burden and the need for well-trained interviewers to use appropriate prompts and score the open-ended responses. The Diabetes Behavior Rating Scale (DBRS) is a self-administered, fixed-choice survey. RESEARCH DESIGN AND METHODS: Both measures were administered to 146 youth with type 1 diabetes (aged 11-18 years) and their parents. Items were ... Read More »
» Published in Diabetes Care. 2006 Oct;29(10):2263-7.

14. Influence of everolimus on cyclosporine Neoral pharmacokinetics in Chinese de novo cardiac transplant recipients.
Match Strength: 3.267

OBJECTIVE: This study sought to determine the influence of everolimus on cyclosporine Neoral (CsA) pharmacokinetics over the first 6 months after heart transplantation in Chinese recipients. METHODS: Six de novo cardiac recipients receiving a CsA-everolimus-based immunosuppressive regimen after rabbit antithymoglobulin sequential immuno-induction were compared with six age-matched recipients receiving a CsA-azathioprine-based regimen. We compared CsA 12-hour area-under-curve (AUC) of the first dose (PK-1) and steady state dose (PK-S) at 1 month after transplantation. The CsA trough ... Read More »
» Published in Transplant Proc. 2006 Sep;38(7):2032-4.

15. Long-term engraftment of p18(INK4C)-deficient hematopoietic stem cells is enhanced in the sublethally-irradiated recipients.
Match Strength: 3.235

Non-myeloablative regimens for host conditioning have been widely used in clinical hematopoietic stem cell transplantation due to their reduced toxicity on the recipients. But a milder conditioning regimen may require a higher engrafting ability of donor stem cells in competing with endogenous stem cells. Thus, new strategies for enhancing the competitiveness of donor stem cells in non-myeloablative recipients would have important implications for current clinical stem cell transplantation. It is known that the absence of p18(INK4C) (p18) gene can enhance the self-renewal potential of ... Read More »
» Published in Sci China C Life Sci. 2006 Aug;49(4):390-4.

16. Severe mucositis is associated with reduced survival after autologous stem cell transplantation for lymphoid malignancies.
Match Strength: 3.078

Mucositis is a known complication of autologous stem cell transplantation (ASCT). This study retrospectively reviewed 191 patients with lymphoid malignancies undergoing ASCT following a uniform mobilising regimen of etoposide (VP-16)/granulocyte colony-stimulating factor and a uniform high-dose preparative regimen of busulfan/cyclophosphamide/VP-16. Eighty-seven patients experienced severe mucositis (modified Oral Mucositis Assessment Scale > or =1). Patient characteristics compared between mucositis groups were balanced according to disease status, prior exposure to radiation therapy, time ... Read More »
» Published in Br J Haematol. 2006 Nov;135(3):374-81. Epub 2006 Sep 22.

17. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.
Match Strength: 3.048

The safety, immunogenicity, and efficacy of DNA and modified vaccinia virus Ankara (MVA) prime-boost regimes were assessed by using either thrombospondin-related adhesion protein (TRAP) with a multiple-epitope string ME (ME-TRAP) or the circumsporozoite protein (CS) of Plasmodium falciparum. Sixteen healthy subjects who never had malaria (malaria-naive subjects) received two priming vaccinations with DNA, followed by one boosting immunization with MVA, with either ME-TRAP or CS as the antigen. Immunogenicity was assessed by ex vivo gamma interferon (IFN-gamma) enzyme-linked immunospot assay ... Read More »
» Published in Infect Immun. 2006 Oct;74(10):5933-42.

18. Very low-carbohydrate versus isocaloric high-carbohydrate diet in dietary obese rats.
Match Strength: 2.962

OBJECTIVE: The effects of a very low-carbohydrate (VLC), high-fat (HF) dietary regimen on metabolic syndrome were compared with those of an isocaloric high-carbohydrate (HC), low-fat (LF) regimen in dietary obese rats. RESEARCH METHODS AND PROCEDURES: Male Sprague-Dawley rats, made obese by 8 weeks ad libitum consumption of an HF diet, developed features of the metabolic syndrome vs. lean control (C) rats, including greater visceral, subcutaneous, and hepatic fat masses, elevated plasma cholesterol levels, impaired glucose tolerance, and fasting and post-load insulin resistance. Half of the ... Read More »
» Published in Obesity (Silver Spring). 2006 Aug;14(8):1344-52.

19. Percutaneous absorption of crotamiton in man following single and multiple dosing.
Match Strength: 2.754

PURPOSE: Crotamiton is a topical drug used in the treatment of scabies and pruritus. We determined its percutaneous absorption following single and multiple dosing in normal skin. METHODS: We used in vivo measurement of percutaneous absorption of [14C] crotamiton in a multidose regimen by measuring urinary excretion and liquid scintillation counting in three groups of four healthy volunteers. The Feldmann urinary excretion method was utilized to ascertain percutaneous absorption. Our results showed that tape stripping does not increase percutaneous absorption of crotamiton; upon repeated ... Read More »
» Published in Cutan Ocul Toxicol. 2006;25(3):211-6.

20. How language barriers impact patient care: a commentary.
Match Strength: 2.642

The population of the United States population is growing more diverse at a rapid rate through the 21st century. Health care providers are interacting more frequently with patients of diverse ethnic affiliations where health beliefs, languages, and life experiences may differ greatly from their own. According to Timmins (2002), "...the U.S. health care system is largely geared toward serving English speakers." This is because language is the most common barrier in any health care setting and has been found to be a risk factor with adverse outcomes. Health care providers and patient ... Read More »
» Published in J Cult Divers. 2006 Fall;13(3):168-9.

 << Prev 20  Showing results 1 to 20 of 67 Next 20 >>




* All information on Level1Diet.com is for educational purposes only. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Before changing your diet, or adding supplements to your diet, or beginning an exercise program, everyone should consult a qualified and licensed health practitioner; a physician, dietician or similar professional.



spacer spacer
spacer
Level1Diet.com foods to eat...
   


DO YOU KNOW ?
Over 1,532 new health studies are published every day ― 559,288 per year. Join our weekly update program to stay informed...
spacer

spacer
» About Health Updates


spacer

HAVE WE
HELPED YOU?

Donate $5 or $10
to help us promote
anti-inflammatory health.


spacer
Bigger Font Size Smaller Font Size Left Align Justify Align Right Align Bookmark This Page
spacer
Search 3.1 Million
Health Studies


» List of 4,000+ Diseases
spacer
   

spacer




Subscribe to
Level1Diet.com
Health Reports


Add to Google Reader or Homepage
Subscribe in NewsGator Online
Subscribe in Bloglines
Add to Excite MIX
Add to netvibes
Add to fwicki
Add to My AOL
Add to The Free Dictionary



About Us Contact Us Privacy Free Newsletter Health FAQs Terms of Use

 Subscribe in a reader

© 2010 Level1Diet.com, All Rights Reserved.     Contact:

Replace omega-6 vegetable oils with omega-9 olive oil... Eat oily fish like tuna, sardines, anchovy, salmon, herring... Beans, lentils, peas add fiber... Nine or more 3-ounce servings of fruits or vegetables per day...